Protein Chromatography Cleaning Validation Patents: Leaders & White Space 2026
- A ten-filer leader sits well ahead of a field of 21 ranked companies, with the fifth-place company at 5 records and tenth place at just 3 — a sharp drop-off rather than a gradual tail.
- B01D separation-process claims cover 75.9% of the 54 records in scope, while G01N testing/analysis claims sit at 48.1% — cleaning validation is being claimed mostly as apparatus and process, not as an analytical method.
- Filings peaked in 2017 at 9 records and have declined since, though the most recent years are understated by the usual 18-month publication lag.
What this landscape covers
Cleaning validation for protein chromatography sits at the intersection of separation hardware, residue and carryover testing, and the biologics manufacturing processes the columns serve. This dataset pulls 54 published records filed against a search built around Protein A and affinity chromatography combined with cleaning-cycle, residue-limit and resin-recovery language, scoped to the IPC classes covering separation processes, peptide chemistry and enzymatic production.
Because a single record can carry several IPC codes, the technology composition below is read against the full 54-record base rather than against itself — a filing claiming both a resin regeneration process and an analytical residue assay appears in two class counts at once.
Filing trend and technology mix
Two views of the same 54-record set: how filing activity has moved year over year, and how those records split across the IPC subclasses that define the technical approach.
Filing trend, 2017 peak
Filings peaked at 9 records in 2017 and have tapered toward 2026, which is a partial year. Publication lag of roughly 18 months means the last one to two years will always read lower than the eventual final count, so the recent decline should not be read as the field going cold without checking again in a year.
Where the claims concentrate
B01D (separation processes) appears in 75.9% of the 54 records, making it the dominant class by a wide margin. G01N (testing and analysis) follows at 48.1%, C07K (peptides and proteins) at 35.2%, and B01J (catalytic and physical processes) at 24.1%. The lighter classes — C12P and C12R fermentation-related codes at 16.7% each, C12N genetic engineering at 13.0%, and A61K medicinal preparations at 5.6% — show cleaning validation is claimed mostly as hardware and process rather than as a formulation or biological question.
Shares are the percentage of the 54 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Protein Chromatography Cleaning Validation with Eureka
This page is one run against one query. Ask Eureka your own question about protein chromatography cleaning validation and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
CA2922832A1 — Method for chromatography reuse (Genentech)
The present invention provides methods for cleaning or regenerating a chromatography materiel for reuse. The methods of the invention can be used for cleaning or regenerating chromatography columns for reuse in the large-scale manufacture of multiple polypeptide products.Filed 2015-03-12, this record frames cleaning and regeneration as a reuse strategy for large-scale polypeptide manufacture rather than as a one-off maintenance step, which is why it recurs in later prosecution around column reuse cycles.
View full record in Eureka| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20030170810A1 | Methods and apparatuses for purification | 68 |
| 2 | US8506802B1 | Stackable planar adsorptive devices | 66 |
| 3 | US4802981A | Automatic chromatography apparatus | 44 |
| 4 | US5258497A | Process for purifying annexines | 34 |
| 5 | EP0317114A1 | Automatic chromatography apparatus | 30 |
| 6 | WO2015035180A1 | Method for chromatography reuse | 25 |
| 7 | WO2015023678A1 | Stackable planar adsorptive devices | 15 |
| 8 | US4861488A | Automatic chromatography process | 12 |
| 9 | US5977345A | Inside-out crosslinked and commercial-scale hydrogels, and sub-macromolecular selective purification using th… | 9 |
| 10 | WO2003025156A2 | Methods and apparatuses for purification | 8 |
Citation counts favour older filings simply because they have had more time to be cited — read them as markers of influence on later drafting, not as a signal of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three read-throughs from the trend, class mix and citation data — useful for deciding where a new filing is likely to land on clean ground versus dense prior art.
Activity has cooled since 2017, but the tail is uncertain
The trend line runs from 9 records in 2017 down toward 0 by 2026. Growth rate is not computable from this data because too few complete years remain once the 18-month publication lag is stripped out, so the honest read is a plateau-to-decline pattern rather than a confirmed downturn.
Apparatus and process claims dominate over analytical method claims
B01D covers three in four records while G01N, the testing and analysis class, covers under half. That gap suggests residue and carryover detection methods are claimed less densely than the separation hardware and cycle steps around them.
A clear leader, then a fast drop to single digits
The leading company holds 10 records against a fifth-place company at 5 and a tenth-place company at 3, out of 21 ranked companies in total. That is a steep early drop rather than a smooth long tail, which usually means the leader's early filings set the claim boundaries others are now working around.
The most-cited records predate the current cleaning-validation wave
The top-cited filings are general chromatography apparatus patents rather than cleaning-specific ones, which means the foundational prior art a new filer must clear sits outside the narrow cleaning-validation claim set itself.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to protein chromatography cleaning validation, with the prior art for and against each one.
Who is filing and where the gaps sit
The ranked list covers 21 companies total, with a pronounced gap between the leader and the rest. Momentum in the latest full year is flat across the companies tracked, consistent with the overall 2026 filing count of zero for a still-incomplete year.
One company set an early pace the field has not matched
The top-ranked company holds 10 of the records in the assignee ranking, well clear of the 5 held by the fifth-place company. Its filings anchor much of the separation-process claim space the rest of the field is filing around.
A small group of repeat filers sits below the leader
Fifth place holds 5 records, marking a clear step down from the leader but still above the single-digit entrants that make up most of the rest of the ranked list.
The ranking thins quickly past the top few names
Tenth place holds just 3 records, and the drop from leader to tenth place is steep rather than gradual — a pattern that usually means later entrants are filing narrower, more defensive claims rather than broad platform patents.
| Assignee | Recent year | YoY |
|---|---|---|
| Boehringer Ingelheim International GmbH | 0 | — |
| Repligen Corporation | 0 | — |
| SPF TECHNOLOGIES LLC | 0 | — |
| OROS SYST | 0 | — |
| Affinium Pharmaceuticals Inc. | 0 | — |
| Genentech, Inc. | 0 | — |
| VEDADI MASOUD | 0 | — |
| NARROL MATT | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio benchmarking or identifying open filing space.
Check freedom-to-operate against the leader's claims
With one company holding 10 of the ranked records, any new cleaning-cycle or resin-recovery filing should be checked against that company's claim scope before drafting.
Run a claims check in EurekaMap the under-claimed testing branch
G01N testing and analysis claims cover under half the records against B01D's three-quarters, suggesting analytical residue-detection methods carry more open claim space than the separation hardware around them.
Explore the technology map in EurekaWatch for the 2026 filing catch-up
The apparent decline toward 2026 is partly a publication-lag artefact; revisiting the trend in a year will show whether filing activity actually cooled or simply has not published yet.
Track filing trends in EurekaCommon questions on this landscape
One company leads the ranked list with 10 records, ahead of a fifth-place company at 5 and a tenth-place company at 3, out of 21 companies in the full ranking. The drop from the leader to the rest of the field is steep rather than gradual, which typically means the leader's early filings shaped much of the claim space others now file around. This dataset covers 54 published records in total, so the leader's share should be read against that record count rather than assumed to be a majority.
Filings peaked at 9 records in 2017 and have declined toward 2026, which is a partial year in this dataset. A firm growth or decline rate cannot be computed from this evidence because too few complete years remain once the roughly 18-month gap between filing and publication is accounted for. The honest reading is that the field has cooled from its 2017 peak, with the final verdict on the most recent years still pending as more records publish.
Separation-process claims under IPC class B01D appear in 75.9% of the 54 records in scope, making apparatus and process claims the dominant category. Testing and analysis claims under G01N follow at 48.1%, and peptide-chemistry claims under C07K at 35.2%. Because a record can carry multiple IPC classes, these shares add up to more than 100%, and the pattern suggests the field is claimed more as hardware and cleaning process than as analytical detection method or formulation.
CA2922832A1, filed 2015-03-12, describes methods for cleaning or regenerating a chromatography material for reuse, specifically framed around reusing chromatography columns in large-scale manufacture of multiple polypeptide products. It treats cleaning and regeneration as part of a repeated-use manufacturing cycle rather than a one-time maintenance step. Anyone drafting claims around column reuse cycles in a comparable large-scale biologics context should check this filing's claim scope directly rather than relying on the abstract alone.
The gap between B01D's 75.9% coverage and G01N's 48.1% coverage points to analytical residue and carryover detection methods as a relatively less-claimed branch compared with the separation hardware and cleaning-cycle process claims around them. Sub-areas such as detergent residue assay methods, rinse-sample carryover thresholds, and enzymatic cleaning agent formulations show lighter representation in the IPC mix. Confirming true white space still requires a claims-level search rather than relying on class-level shares alone.
Research Protein Chromatography Cleaning Validation in depth with Eureka
Go past this page: query the whole protein chromatography cleaning validation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.